Development of Erf-mediated craniosynostosis and pharmacological amelioration
ETS2 repressor factor (<i>ERF</i>) insufficiency causes craniosynostosis (CRS4) in humans and mice. ERF is an ETS domain transcriptional repressor regulated by Erk1/2 phosphorylation via nucleo-cytoplasmic shuttling. Here, we analyze the onset and development of the craniosynostosis phen...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
MDPI
2023
|
| _version_ | 1826310561895284736 |
|---|---|
| author | Vogiatzi, A Keklikoglou, K Makris, K Richardson, MSW Fenwick, AL Robertson, J Twigg, SRF Wilkie, AOM |
| author_facet | Vogiatzi, A Keklikoglou, K Makris, K Richardson, MSW Fenwick, AL Robertson, J Twigg, SRF Wilkie, AOM |
| author_sort | Vogiatzi, A |
| collection | OXFORD |
| description | ETS2 repressor factor (<i>ERF</i>) insufficiency causes craniosynostosis (CRS4) in humans and mice. ERF is an ETS domain transcriptional repressor regulated by Erk1/2 phosphorylation via nucleo-cytoplasmic shuttling. Here, we analyze the onset and development of the craniosynostosis phenotype in an Erf-insufficient mouse model and evaluate the potential of the residual Erf activity augmented by pharmacological compounds to ameliorate the disease. Erf insufficiency appears to cause an initially compromised frontal bone formation and subsequent multisuture synostosis, reflecting distinct roles of Erf on the cells that give rise to skull and facial bones. We treated animals with Mek1/2 and nuclear export inhibitors, U0126 and KPT-330, respectively, to increase Erf activity by two independent pathways. We implemented both a low dosage locally over the calvaria and a systemic drug administration scheme to evaluate the possible indirect effects from other systems and minimize toxicity. The treatment of mice with either the inhibitors or the administration scheme alleviated the synostosis phenotype with minimal adverse effects. Our data suggest that the ERF level is an important regulator of cranial bone development and that pharmacological modulation of its activity may represent a valid intervention approach both in CRS4 and in other syndromic forms of craniosynostosis mediated by the FGFR-RAS-ERK-ERF pathway. |
| first_indexed | 2024-03-07T07:53:46Z |
| format | Journal article |
| id | oxford-uuid:f28a1a2b-2091-4c0f-90c6-993743b0b37d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:53:46Z |
| publishDate | 2023 |
| publisher | MDPI |
| record_format | dspace |
| spelling | oxford-uuid:f28a1a2b-2091-4c0f-90c6-993743b0b37d2023-08-01T18:01:03ZDevelopment of Erf-mediated craniosynostosis and pharmacological ameliorationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f28a1a2b-2091-4c0f-90c6-993743b0b37dEnglishSymplectic ElementsMDPI2023Vogiatzi, AKeklikoglou, KMakris, KRichardson, MSWFenwick, ALRobertson, JTwigg, SRFWilkie, AOMETS2 repressor factor (<i>ERF</i>) insufficiency causes craniosynostosis (CRS4) in humans and mice. ERF is an ETS domain transcriptional repressor regulated by Erk1/2 phosphorylation via nucleo-cytoplasmic shuttling. Here, we analyze the onset and development of the craniosynostosis phenotype in an Erf-insufficient mouse model and evaluate the potential of the residual Erf activity augmented by pharmacological compounds to ameliorate the disease. Erf insufficiency appears to cause an initially compromised frontal bone formation and subsequent multisuture synostosis, reflecting distinct roles of Erf on the cells that give rise to skull and facial bones. We treated animals with Mek1/2 and nuclear export inhibitors, U0126 and KPT-330, respectively, to increase Erf activity by two independent pathways. We implemented both a low dosage locally over the calvaria and a systemic drug administration scheme to evaluate the possible indirect effects from other systems and minimize toxicity. The treatment of mice with either the inhibitors or the administration scheme alleviated the synostosis phenotype with minimal adverse effects. Our data suggest that the ERF level is an important regulator of cranial bone development and that pharmacological modulation of its activity may represent a valid intervention approach both in CRS4 and in other syndromic forms of craniosynostosis mediated by the FGFR-RAS-ERK-ERF pathway. |
| spellingShingle | Vogiatzi, A Keklikoglou, K Makris, K Richardson, MSW Fenwick, AL Robertson, J Twigg, SRF Wilkie, AOM Development of Erf-mediated craniosynostosis and pharmacological amelioration |
| title | Development of Erf-mediated craniosynostosis and pharmacological amelioration |
| title_full | Development of Erf-mediated craniosynostosis and pharmacological amelioration |
| title_fullStr | Development of Erf-mediated craniosynostosis and pharmacological amelioration |
| title_full_unstemmed | Development of Erf-mediated craniosynostosis and pharmacological amelioration |
| title_short | Development of Erf-mediated craniosynostosis and pharmacological amelioration |
| title_sort | development of erf mediated craniosynostosis and pharmacological amelioration |
| work_keys_str_mv | AT vogiatzia developmentoferfmediatedcraniosynostosisandpharmacologicalamelioration AT keklikoglouk developmentoferfmediatedcraniosynostosisandpharmacologicalamelioration AT makrisk developmentoferfmediatedcraniosynostosisandpharmacologicalamelioration AT richardsonmsw developmentoferfmediatedcraniosynostosisandpharmacologicalamelioration AT fenwickal developmentoferfmediatedcraniosynostosisandpharmacologicalamelioration AT robertsonj developmentoferfmediatedcraniosynostosisandpharmacologicalamelioration AT twiggsrf developmentoferfmediatedcraniosynostosisandpharmacologicalamelioration AT wilkieaom developmentoferfmediatedcraniosynostosisandpharmacologicalamelioration |